Abstract: The present invention provides an epithelial cancer therapeutic agent with less side effects. In order to achieve the above object, an epithelial cancer therapeutic agent of the present invention includes: at least one material selected from the group consisting of oxo acid, oxo acid ion, and oxo acid salt, wherein the epithelial cancer therapeutic agent treats or prevents epithelial cancer.

Abstract: A spheroid formation promoter, including: inorganic particles having adsorbability as an active ingredient; and a method of promoting spheroid formation, including the step of: mixing a dispersion liquid of the spheroid formation promoter and a cell suspension to obtain a mixture in which the inorganic particles having adsorbability contained in the spheroid formation promoter are dispersed, and culturing a cell contained in the obtained mixture to promote spheroid formation.

Abstract: An object of the invention is to provide a method for detecting cancer in a simple and highly accurate manner, and a reagent that can be used in the method. A method for detecting cancer (excluding renal cell cancer), which comprises measuring the level of Azurocidin (AZU1) in a sample, in which it is determined that cancer is detected when a measured value exceeds a preset reference value. The cancer is preferably selected from the group consisting of stomach cancer, breast cancer, colorectal cancer, and lung cancer. A reagent containing an antibody that specifically recognizes AZU1 is used in detecting cancer (excluding renal cell cancer).

Abstract: Provided is a method wherein an affected tissue and a normal tissue obtained from the vicinity of the affected tissue are left at rest in a culture medium, and a disease-specific biomarker is searched for in an exudate therefrom. A biomarker specific to renal cell carcinoma has been found by this method.

Abstract: The present invention aims to provide a compound capable of inhibiting PCA-1 that can be a target for a novel treatment method of various diseases, and pharmaceutical use of the compound. A compound represented by the formula (I): wherein each symbol is as defined in the DESCRIPTION, or a pharmaceutically acceptable salt thereof.

Abstract: The present invention aims to provide a compound capable of inhibiting PCA-1 that can be a target for a novel treatment method of various diseases, and pharmaceutical use of the compound. A compound represented by the formula (I): wherein each symbol is as defined in the DESCRIPTION, or a pharmaceutically acceptable salt thereof.

Abstract: Disclosed is an apoptosis promoter, cell proliferation inhibitor, prophylactic/therapeutic agent for cancer or the like which comprises a compound capable of inhibit the expression or function of PCA-1 as an active ingredient. Also disclosed is a method for screening of a compound for use in the promotion of apoptosis, the inhibition of cell proliferation or the prevention/treatment of cancer, which comprises selecting a compound capable of inhibit the expression or function of PCA-1, or the like.

Abstract: The present invention provides a method for detecting and/or quantifying PCA-1 in a body fluid sample from a subject as a prostate cancer marker. The present invention also provides a method for detecting and/or quantifying an anti-PCA-1 autoantibody in a body fluid sample from a subject as a prostate cancer marker. The present invention allows diagnosis of prostate cancer to be performed more simply, more rapidly and at lower cost.

Abstract: Antibodies to a LAR phosphatase subunit, particularly antibodies having specificity to an intracellular domain of a phosphatase subunit, methods for generation thereof and cells producing these antibodies, and determination and examination methods of LAR/LAR derived molecules using these antibodies, as well as uses of these antibodies in diagnosis and therapy of thyroid cancer are disclosed.

Abstract: The present invention relates to a method for determining a subject having a risk of having developed or developing prostate cancer, which comprises the following steps: a) a step of analyzing the presence/absence or level of mutation in the PCA-1 gene derived from the subject; and b) a step of evaluating the presence/absence or level of the subject's risk of having developed or developing prostate cancer, based on the presence/absence or level of mutation in the PCA-1 gene. According to the determination method of prostate cancer of the present invention, a subject having a risk of having developed or developing prostate cancer can be determined conveniently and highly sensitively. Therefore, the method is effective for the diagnosis of prostate cancer, progress monitoring, prognostic prediction, diagnosis before the onset, carrier diagnosis and the like.

Abstract: Antibodies to intracellular domains of two or more kinds of protein tyrosine phosphatases, methods for generation thereof and cells producing these antibodies are disclosed. The antibody of the present invention may have specificity to intracellular domains of phosphatase subunits of both of LAR and CD45, and may be useful for analysis and quantitative determination of PTPs, identification and detection of novel PTPs, and for obtaining novel phosphatases by cloning and the like, as well as for developing useful diagnostic methods of insulin resistance and NIDDM, for prophylaxis and diagnosis of various disease states of syndrome X that is based on insulin resistance, and for prophylaxis and diagnosis of onsets of arteriosclerosis and cardiac diseases.

Abstract: Antibodies to a LAR phosphatase subunit, particularly antibodies having specificity to an intracellular domain of a phosphatase subunit, methods for generation thereof and cells producing these antibodies, and determination and examination methods of LAR/LAR derived molecules using these antibodies, as well as uses of these antibodies in diagnosis and therapy of thyroid cancer are disclosed.

Abstract: Antibodies to a LAR phosphatase subunit, particularly antibodies having specificity to an intracellular domain of a phosphatase subunit, methods for generation thereof and cells producing these antibodies, and determination and examination methods of LAR/LAR derived molecules using these antibodies, as well as uses of these antibodies in diagnosis and therapy of thyroid cancer are disclosed.

Abstract: Antibodies to a LAR phosphatase subunit, particularly antibodies having specificity to an intracellular domain of a phosphatase subunit, methods for generation thereof and cells producing these antibodies, and determination and examination methods of LAR/LAR derived molecules using these antibodies, as well as uses of these antibodies in diagnosis and therapy of thyroid cancer are disclosed.

Abstract: Antibodies to a LAR phosphatase subunit, particularly antibodies having specificity to an intracellular domain of a phosphatase subunit, methods for generation thereof and cells producing these antibodies, and determination and examination methods of LAR/LAR derived molecules using these antibodies, as well as uses of these antibodies in diagnosis and therapy of thyroid cancer are disclosed.